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Investigation of cellular uptake of metal compounds is important in understanding metal-related
toxicity and diseases. Inhalation of beryllium aerosols can cause chronic beryllium disease, a
progressive, granulomatous fibrosis of the lung. Studies in laboratory animals and cultured
animal cells indicate that alveolar macrophages take up beryllium compounds and participate in a
hypersensitivity immune response to a beryllium-containing antigen. In the present work, human
monocyte cell line THP-1 was induced with phorbol myristate acetate to differentiate into a
macrophage. This cell with characteristics of human alveolar macrophages was employed to study
cellular beryllium uptake and related biological effects. Morphological changes, phagocytosis of
fluorescent latex beads, and cell surface CD14 expression were used to verify the successful
differentiation of THP-1 monocytes into macrophages. An improved mass spectrometry method
for quantitative analysis of intracellular beryllium as opposed to the traditional radioisotopic
approach was developed using ICP-MS. The influence of the solubility of beryllium compounds,
exposure duration, and beryllium concentration on the incorporation of beryllium was studied.
Our data indicated that the uptake of particulate BeO was much more significant than that of
soluble BeSO4, suggesting the major cellular uptake pathway is phagocytosis. Nevertheless,
subsequent DAPI nuclear staining and PARP cleavage study indicated that beryllium uptake had
a negligible effect on the apoptosis of THP-1 macrophages compared to the unstimulated
macrophage control. Meanwhile, no substantial variation of tumour necrosis factor-alpha
production was observed for THP-1 macrophages upon beryllium exposure. These data imply
alveolar macrophages could have some level of tolerance to beryllium and this may explain
why most Be-exposed individuals remain healthy throughout life.
Introduction
Beryllium, the lightest stable metal, possesses many unique
physical and chemical properties that make it an ideal choice
as a material for high-technology industries, such as aerospace,
nuclear defense, and electronics. However, environmental
exposure to beryllium, even at very low concentrations, can
trigger beryllium sensitization (BeS) and chronic beryllium
disease (CBD), a granulomatous lung disease resulting from a
delayed-hypersensitivity, cell-mediated immune response to
beryllium.1 BeS represents the proliferative responses of
beryllium-specific T cells in the blood and/or bronchoalveolar
lavage (BAL) of beryllium-exposed workers, and the rate of
progression from BeS to CBD has been estimated to be about
6% to 8% per year.2 Depending on the nature of beryllium
exposure and the individual’s genetic susceptibility, CBD will
eventually develop in 2-16% of these subjects.3–5 The current
understanding of how CBD develops is that inhaled beryllium
is taken up by alveolar macrophages and processed by
the MHC class II pathway, possibly via binding to an
as-yet-unidentified peptide. This Be-peptide complex is
subsequently presented by the HLA-DP heterodimers formed
on the surface of the antigen-presenting cells and recognized
by some Be-specific CD4+ T cell clones, which initiate a
host immune response.6–10 However, the true identity of the
beryllium antigen remains only speculative and it is not
completely clear how the beryllium initially enters the cell.
Information about the interaction of beryllium with lung
macrophages is important because these cells play central
roles in handling environmental burdens, generating chronic
inflammatory responses, and participating in the sensitization
of T lymphocytes in cell-mediated immune responses.11 In the
respiratory tract, alveolar macrophage cells are among the first
lung cells to be exposed to inhaled foreign substances, such as
particulate beryllium. However, due to the inconvenience and
difficulty of obtaining an adequate amount of BAL cells,
very limited investigation on cellular beryllium uptake using
alveolar macrophages has been reported.11,12 These studies,
which used laboratory animals, along with reports on intra-
venous administration to rat liver cells13,14 and studies of
cultured animal cells,15,16 indicate that particulate forms
(e.g., beryllium phosphate) are taken up to a markedly greater
extent than soluble salts (e.g., beryllium sulfate). Yet, the
results obtained from animal cells cannot be directly extrapolated
to humans because of species differences.
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The human monocytic leukemia cell line THP-1 develops
macrophage functions following inducement by phorbol
myristate acetate (PMA), and has been shown to be a good
model for in vitro-differentiated, monocyte-derived macro-
phages.17,18 The THP-1 differentiated macrophage has been
extensively characterized,19,20 and its many cytochemical and
immunological characteristics, such as lysozyme production,
phagocytic activity, and capacity of response to T-lymphocyte,
resemble alveolar macrophages of human origin. Due to
metabolic and morphological similarities, THP-1 differentiated
macrophages have been widely used as an in vitro model in the
study of alveolar macrophage involvement in inflammatory
diseases.21–24 Considering cell culture offers the advantages of
no donor variability in macrophage function and that large
numbers of cells can be grown reproducibly, in this study,
we seek to use THP-1 differentiated macrophages to mimic
human alveolar macrophages for a cellular beryllium uptake
and related biological effects study.
In all the aforementioned cellular beryllium uptake studies
using laboratory animals or cultured animal cells, radioactive
isotope labeling (7Be, half-life of 53 d) has been used exclusively
to ensure detection sensitivity. However, radioisotopes
have inherent problems associated with safety hazards,
legal requirements, and regulations for storage and disposal.
Technology development in atomic spectroscopy has enabled
accurate and sensitive measurement of metal concentrations
by more convenient and eco-friendly means. Inductively
coupled plasma mass spectrometry (ICP-MS) is a powerful
tool for the elemental analysis of biological samples.25–27 In
the present work, a new analytical approach for measuring
cellular beryllium content was developed using ICP-MS in
place of conventional radioactive isotope labeling. The influence
of the solubility of beryllium compounds, exposure duration,
and beryllium concentration on the incorporation of beryllium
was studied. Apoptosis and tumor necrosis factor-alpha
(TNF-a) production were investigated to evaluate the biological
effects of beryllium on THP-1 differentiated macrophages.
Materials and methods
Chemicals and reagents
PMA (Sigma, St. Louis, MO, USA) was prepared as a solution
of 2 mg/mL in dimethyl sulfoxide, aliquoted and frozen.
A PMA aliquot was then diluted with cell culture medium to
obtain a stock solution of 1 mg/mL, to be used at a final
concentration of 100 ng/mL for THP-1 cell inducement. A
stock solution of 100 mM BeSO4 (Alfa Aesar China, Tianjing)
and a stock suspension of 25 mM BeO (Sinopharm Chemical
Reagent Co., Ltd., Shanghai, China) were prepared in deionized
water. Before being added into the cell culture medium, the
BeO stock suspension was sonicated for 5–10 min. Due to the
propensity of beryllium salts to form beryllium phosphate in
the presence of inorganic phosphate, a 0.9% NaCl solution
was used instead of PBS as the balanced salt solution. A 1-M
sulfosalicylic acid (SSA, Sinopharm Chemical Reagent Co.,
Ltd.) solution was prepared in 0.9% NaCl solution, and when
used, diluted to a concentration of 100 mM. A stock
solution of 1 mg/mL 2-(4-amidinophenyl)-6-indolecarbamidine
dihydrochloride (DAPI, Sigma) was prepared in deionized
H2O and diluted to 1 mg/mL in PBS when used to stain the
cells. Doxycycline was purchased from Sigma. All the
other reagents were of analytical grade. The fluorescein
isothiocyanate (FITC) labeled mouse anti-human CD14
monoclonal antibody (mAb) and the mouse IgG2b FITC/
Isotype Control were purchased from Beijing CellChip
Biotechnology Co., Ltd., Beijing, China. Poly-ADP-ribose
polymerase (PARP) mAb, b-actin mAb, and goat anti-mouse
IgG were purchased from BD Biosciences (NJ, USA),
Santa Cruz Biotechnology (Santa Cruz, CA, USA), and
Thermo Scientific (Rockford, IL, USA), respectively.
Cellular culture and differentiation
The THP-1 cell line was purchased from the Cell Bank of the
Type Culture Collection of the Chinese Academy of Sciences,
Shanghai, China. THP-1 cells were cultured in RPMI 1640
medium supplemented with 10% heat-inactivated, fetal bovine
serum (FBS), 100 U/mL penicillin, 100 mg/mL streptomycin,
2.05 mM L-glutamine, 1 mM sodium pyruvate (all from
Hyclone Co., Logan, UT, USA), 10 mM HEPES, 0.05 mM
2-mercaptoethanol, and 2.5 g/L D-glucose (all from Amresco
Co., San Diego, CA, USA). Cells were maintained in continuous
culture at 37 1C in 5% CO2 and 95% air. Before PMA
inducement, cell viability as determined by trypan blue exclusion
was 495% in all experiments. The cells were counted
manually using a hemacytometer under the light microscope.
Differentiation was achieved by plating 10 mL of the THP-1
monocytes suspended in growth medium containing 100 ng/mL
PMA (5.0  105 cells/mL) into 100-mm Falcon culture dishes,
and then culturing for 48 h or other indicated periods of time.
After aspirating the medium, the differentiated THP-1
macrophage cells were washed twice with 0.9% NaCl solution.
Optimal differentiation conditions were identified with CD14
expression measurement and a phagocytic activity test.
Beryllium uptake protocol and ICP-MS measurement
Ten micromolar and one hundred micromolar BeSO4 or BeO
supplemented in culture medium were used for macrophage
treatments, as these concentrations have been reported to be
within the optimal stimulatory concentration range.7,28,29
A schematic of the experimental design for the cellular beryllium
uptake study is shown in Fig. 1. Briefly, THP-1 differentiated
macrophages were stimulated with beryllium for 48 h or other
indicated periods of time at 37 1C in a humidified, 5% CO2
atmosphere. The cells were washed five times with 0.9% NaCl
solution. After the second wash, the cells were incubated in
0.9% NaCl containing 100 mM of SSA for 10 minutes. The
final (fifth) washing solutions were collected. After the
final plate washing, the macrophages were harvested (0.25%
trypsin treated for 90–150 s, counted, and centrifuged) and
resuspended in 150 mL of deionized water and 250 mL of
concentrated, ultrapure-grade HNO3 (Alfa Aesar China) was
added. After 5 min of sonication, the mixture was heated at
80 1C on a metallic heating plate for 2 h. The beryllium
content of the digested cell samples and the collected washing
solutions were analyzed on an Agilent 4500 ICP-MS. An equal
concentration of Rh (10 ng/mL) was added to all blanks,























































standards, and samples to serve as an internal standard.
The detection limit of Be was 0.3 pg/mL and the recoveries
for Be-spiked samples were between 92% and 108%. The
detected beryllium concentrations of the cell digests upon
beryllium exposure were all greater than several hundred
pg/mL, well above the detection limit. The average cellular
beryllium content was calculated based on the ICP-MS-detected
beryllium concentration of the cell digest, the digest sample
volume, and the cell number. All experiments were conducted
in triplicate from the point of PMA inducement onward.
Experiments were repeated a minimum of three times, and
representative data are presented.
Phagocytic activity tests
To determine the phagocytic capability of THP-1 macro-
phages, carboxyl fluorescent yellow beads (Spherotech Inc.,
Lake Forest, IL, USA) were added to the medium of the
negative control THP-1 cells and the differentiated macro-
phage cells at a bead-to-cell molar ratio of 45 : 1. After 2 h of
incubation, the differentiated cells were washed twice with PBS
to remove the free beads. The THP-1 control cells were
centrifuged at 1000 rpm (Beckman Coulter Allegra X-15R
Centrifuge) to remove the free beads. Then, the macrophages
and THP-1 control cells were observed under a Ti-U Nikon
fluorescent microscope.
Flow cytometric assays
Flow cytometric measurements were made using a FACSAria
flow cytometer (BD Biosciences, San Jose, CA, USA).
Expression of CD14, a marker known to increase in
differentiated macrophages, was analyzed by incubating a
FITC-conjugated CD14-specific mAb with the differentiated
macrophage cells and the THP-1 control cells. Mouse
IgG2b-FITC was used as a negative isotype control. The cells
were harvested, washed three times with ice-cold PBS, and
resuspended in PBS at 1  106 cells/mL. Then the mAb or the
control isotype was added and incubated at room temperature
for 30 min. After three washes with PBS, the cells were
resuspended in 200 mL of PBS. Flow cytometry analysis was
performed by analyzing 10 000 cell events. THP-1 cells were
gated for analysis by a combination of forward scatter (FSC)
and 901 side scatter (SSC). The percentage of cells positive for
the CD14 marker was determined by setting a cursor on the
negative isotope control to include 98–99% of the population.
Data analysis was performed using BD FACSDiva software
(BD Biosciences).
Nuclear staining with DAPI
For the apoptosis study, THP-1 macrophages were cultured at
1  106 cells/mL with 2 mL per well in NUNC six-well
plates (#150628, Roskilde, Denmark). THP-1 macrophages
were unstimulated, BeSO4-stimulated, BeO-stimulated, and
doxycycline-stimulated for 48 h. After treating the cells with
beryllium compounds, the THP-1 macrophages were washed
with cold PBS and stained with DAPI solution for 15 min at
room temperature. The nuclear morphology of the cells
was examined with a fluorescent microscope (ZEISS AXIO
Imager.A1, Germany). The unstimulated macrophages
were the negative control, and the THP-1 macrophages
induced to apoptosis by 80 mg/mL doxycycline were the
positive control.30
Western blot analysis
The unstimulated, Be-stimulated, and doxycycline-induced
cells (cultured as described in ‘‘Nuclear staining with DAPI’’)
were harvested and lysed with RIPA buffer (150 mM sodium
chloride, 1.0% Triton X-100, 0.5% sodium deoxycholate,
0.1% sodium dodecyl sulfate, 50 mM Tris, pH 8.0). Protein
concentrations were quantified using a Bio-Rad protein assay
(Bio-Rad Laboratories, Hercules, CA, USA), according to the
manufacturer’s instructions. Equal amount of proteins were
subjected to electrophoresis on 10% SDS-polyacrylamide gel
and transferred to a poly(vinylidene difluoride) membrane
(PVDF, GE Healthcare Bio-Sciences Corp., Piscataway,
NJ, USA). The blots were probed with anti-PARP and
anti-b-actin mAbs for 12 h at 4 1C, incubated with the diluted
enzyme-linked goat anti-mouse secondary antibody and
visualized according to the recommended procedure.
Quantification of TNF-a production
The supernatants from BeSO4-stimulated, BeO-stimulated,
and unstimulated THP-1 macrophages and THP-1 monocytes
(cultured as described in ‘‘Nuclear staining with DAPI’’)
were collected by centrifugation at 12 000 rpm for 10 min.
A standard sandwich ELISA assay was performed with a
human TNF-a kit (eBioscience, Camarillo, CA, USA) following
the manufacturer’s instructions. The measured detection limit
of the kit was 4 pg/mL. Dilution was made to the supernatants
to ensure that the detected value falls into the linear dynamic
range of the standard calibration curve. For each sample, three
replicates were carried out in parallel.
Results
Induction of THP-1 cell differentiation into macrophages
CD14 upregulation upon PMA treatment has been reported to
be a surface marker for macrophages.17,31 In order to confirm
Fig. 1 Experiment flowchart for the cellular beryllium uptake study.























































the successful differentiation of THP-1 cells into macrophages,
we analyzed CD14 expression on the cell surface after
PMA inducement. After 24 h of PMA treatment, the confluent
THP-1 cells become adherent and pseudopod spreading of the
macrophages can be observed. However, as shown in Fig. 2,
very few cells (B17%) exhibited an upregulated CD14 expression
after 24 h of inducement. With the treatment time increased to
48 h or longer, a marked increase in CD14 cell surface
expression was identified. Further increase of PMA inducement
duration to 72 h did not yield distinct enhancement of CD14
expression (65% at 48 h versus 70% at 72 h). Therefore, 48 h
was chosen as the optimal PMA inducement time. The
phagocytic capability of the THP-1 macrophages was further
tested using fluorescent beads. After incubation with fluorescent
beads for 2 h, bright fluorescence from beads engulfed within
the macrophage was clearly observed under the microscope,
and the bead number varied from several to 20 per macrophage
cell. On the other hand, no bead uptake could be identified in
the THP-1 monocytes (data not shown).
Examination of cell surface adsorption of beryllium
One obstacle to measuring the uptake of metal compounds is
extracellular binding.32 In order to examine whether cell
surface adsorption of beryllium would occur and how this
would affect the accurate measurement of the intracellular
beryllium content, the extent of cell-surface-adsorbed
beryllium was carefully quantified. Sulfosalicylic acid (SSA)
is a well-known beryllium ligand and was used here to rinse off
any beryllium that may have been nonspecifically adsorbed
onto the cell surface.16 Upon beryllium treatment for 48 h,
the macrophages were washed twice with 0.9% NaCl solution
and then incubated with 100 mM SSA for 10 minutes,
followed by two additional washes (five washes in total,
2 NaCl + 1 SSA + 2 NaCl). Cells not washed with SSA were
processed in parallel as a control. The 5th washing solution
and the harvested cells were analyzed on the ICP-MS. For
beryllium sulfate treatment, the beryllium concentration of the
5th washing solution was marginal regardless of SSA washing.
For beryllium oxide stimulation, the beryllium concentration
of the 5th washing solution was below the detection limit of
ICP-MS. These results indicated that five washes were
adequate to remove the beryllium in the medium. Meanwhile,
for cells treated with 10 mMBeSO4, the beryllium concentrations
measured were 2.51  0.05 ng/mL and 2.63  0.01 ng/mL
for the harvested macrophages with and without SSA
washing, respectively. For cells treated with 100 mM BeSO4,
the beryllium concentrations measured were 6.13  0.09 ng/mL
and 6.43  0.02 ng/mL for the harvested macrophages with
and without SSA washing, respectively. These data indicated
that for cells treated with soluble beryllium sulfate, the cell-
associated beryllium content was about 5% less with SSA
washing than without SSA washing. This reduced value was
defined as ‘‘nonspecific adsorption’’, which is similar to the
B5% cell surface adsorption rate reported in the literature.11
But for particulate forms, nonspecifically adsorbed beryllium
was negligible in comparison to the significant cellular uptake
of beryllium via phagocytosis.
Beryllium compound solubility, incubation duration, and
concentration effects on cellular uptake
The THP-1 differentiated macrophages were cultured in
medium supplemented with BeSO4 or BeO (both were tested
at 10 mM and 100 mM) for 2 h, 4 h, 12 h, 24 h, or 48 h. The
cellular beryllium content was measured by ICP-MS, with the
results shown in Fig. 3. Clearly, cellular beryllium uptake was
much more significant for particulate BeO than for soluble
BeSO4. Within the initial 2 h, the measured cellular beryllium
content levels were 0.21  0.06, 0.23  0.04, 4.61  0.04, and
59.32  1.01 nmol/106 cells for 10 mM BeSO4, 100 mM BeSO4,
10 mM BeO, and 100 mM BeO, respectively. After 48 h of
treatment, cellular beryllium content reached 3.84  0.26,
7.24  0.50, 9.12  0.16, and 78.17  9.04 nmol/106 cells for
10 mM BeSO4, 100 mM BeSO4, 10 mM BeO, and 100 mM BeO,
respectively. For THP-1 macrophages treated with 10 mM
BeO, cellular beryllium uptake increased linearly with time;
for treatment with 100 mM BeO, B75% of the total uptake
was completed within the initial 2 h, indicating that BeO
was readily taken up as a particle. For soluble BeSO4, the
cellular beryllium uptake increased linearly with time, but the
total amount taken up was much lower than for BeO.
Moreover, the amount taken up was not proportional to the
BeSO4 concentration administrated. Meanwhile, in the
control experiment with THP-1 monocytes exposed to
100 mM BeSO4 for 24 h, the measured cellular beryllium
content was 0.65  0.03 nmol/106 cells, which was much lower
than the 3.14  0.41 nmol/106 cells for THP-1 macrophages.
These results indicate that phagocytosis of particulate
beryllium is the major pathway for cellular beryllium uptake.
Cytotoxic effects of cellular beryllium uptake
From the above cellular uptake experiment, it is clear that a
considerable amount of beryllium was taken up by the THP-1
differentiated macrophage. The cytotoxicity of internalized
beryllium on the THP-1 macrophages was examined using
fluorescence microscopy of DAPI staining and Western blot
analysis of the degradation of PARP. Results were compared for
THP-1 macrophages that were untreated (negative control),
BeSO4-stimulated (10 mM or 100 mM), BeO-stimulated
Fig. 2 PMA-stimulated CD14 cell surface expression in THP-1
macrophages. THP-1 monocytes were induced with PMA for 24 h,
48 h, 72 h, or left untreated. Flow cytometric measurements were made
using a FACSAria flow cytometer.























































(10 mM or 100 mM), and doxycycline-stimulated (positive
control) for 48 h. Normally, live cells show uniformly
DAPI-stained, intact nuclei. Late apoptotic cells can be
detected by the fragmentation of DAPI-stained nuclei. As
shown in Fig. 4A, very few apoptotic cells were detected in
unstimulated THP-1 macrophages. Compared to untreated
cells, administration of 10 mM or 100 mM of BeSO4 or BeO did
not result in marked enhancements of the percentage of cells
undergoing late apoptosis. On the other hand, obvious
nuclei fragmentation can be identified for THP-1 macrophages
treated with 80 mg/mL doxycycline.
One of the key initiation elements of the apoptotic pathway
is the activation of caspases, followed by cleavage of the caspase
substrates. The 113-kDa PARP, which is normally involved in
DNA repair, DNA stability, and other cellular events, is
cleaved by members of the caspase family during early
apoptosis. Detection of an 89-kDa or 24-kDa caspase cleavage
fragment of PARP has been used as a hallmark of apoptosis.33
To further examine the apoptotic effect of beryllium
compounds on THP-1 macrophages, PARP cleavage was analyzed
by immunoblotting. In Fig. 4B, all the samples loaded showed a
similar amount of a housekeeping protein (b-actin). Compared
to the untreated control, no distinct PARP cleavage could be
observed for any of the Be-treated THP-1 macrophages while a
cleaved-PARP band was observed for the positive control.
Clearly, both DAPI staining and PARP cleavage studies
indicated that cellular beryllium uptake had negligible cytotoxic
effects on the THP-1 macrophages.
Effect of Be-stimulation on TNF-a production
TNF-a has been reported as a pro-inflammatory cytokine in
specific response to Be-stimulation.34 To determine whether
exposure to beryllium can induce TNF-a secretion in THP-1
macrophages, the TNF-a levels of the culture supernatants
were measured by ELISA for THP-1 macrophages that were
unstimulated or treated with 10 mM BeSO4, 100 mM BeSO4,
10 mMBeO or 100 mMBeO for 24 h or 48 h. For both 24 h and
48 h treatments, the TNF-a levels were all around 1000 pg/mL
(Table 1). The TNF-a level of THP-1 monocytes was also
measured but was undetectable.
Discussion
Investigation of cellular metal uptake using cells of human
origin is important in understanding metal-related toxicity and
diseases.35 In the present work, human monocyte cell line
THP-1 was induced with PMA to differentiate into a macro-
phage. This cell with characteristics of human alveolar macro-
phages was employed to study cellular beryllium uptake and
related biological effects. Morphological changes, phagocytosis
of fluorescent latex beads, and cell surface CD14 expression
were used to verify the successful differentiation of THP-1
monocytes into macrophages by PMA induction. An improved
mass spectrometry method for quantitative analysis of intra-
cellular beryllium as opposed to the traditional radioisotopic
approach was developed using ICP-MS, and satisfactory
recovery rate (92–108%) was obtained. Sulfosalicylic acid, a
beryllium ligand, was used in the cell washing procedure to
ensure efficient rinsing of the beryllium nonspecifically
adsorbed onto the cell surface.
Evidence was obtained in our experiment that THP-1
macrophages took up a considerable amount of beryllium,
with values varying from several to tens of nmol Be/106 cells
depending on the compound solubility, exposure duration,
and compound concentration administrated. These values are
Fig. 3 Uptake of beryllium by THP-1 macrophages as a function of beryllium solubility, incubation duration and beryllium concentration. (A),
(B), (C), (D) Cellular beryllium content for incubation with 10 mM BeSO4, 100 mM BeSO4,10 mM BeO, and 100 mM BeO, respectively. The data
represent the mean  SD of three replicated experiments.























































comparable to the rates of beryllium uptake for cultured
canine pulmonary alveolar macrophages when beryllium
sulfate or beryllium oxide was added12 and for the rat liver
parenchymal cell line and Kupffer cells in culture when
particulate beryllium phosphate, soluble beryllium sulfate, or
a beryllium sulfosalicylate complex was administrated.15,16
Our data support the hypothesis that phagocytosis is the major
mechanism by which the alveolar macrophage incorporates
beryllium.11,12 It is possible that soluble forms of beryllium
could gain entrance into the macrophage via phagocytosis by
first forming insoluble forms of beryllium in the culture
medium. The work of Cheng, and Reeves and Vorwald
suggested that, once in blood, soluble beryllium salts form
and are transported as colloidal particles of beryllium phosphate
and hydroxide.36,37 Due to the presence of phosphate in RPMI
1640 culture medium and its neutral pH, soluble beryllium
sulfate could form both beryllium phosphate and hydroxide in
the culture medium. On the other hand, the addition of serum
globulins to the culture medium can improve the solubility of
beryllium. For beryllium chloride at a concentration of 55 mM,
the percentage of insoluble beryllium decreased from 80% in
basal minimal Eagle’s medium to 10.3% with the presence of
fetal calf serum at a final concentration of 10%.11 So, the
uptake of soluble beryllium sulfate measured in our experiment
might be explained by the balanced effects of the formation of
insoluble complex of beryllium phosphate and hydroxide in the
RPMI-1640 culture medium and the enhanced beryllium
desolvation in the presence of fetal calf serum.
Fig. 4 Cytotoxicity of cellular beryllium uptake on THP-1 macrophages. (A) The macrophages were treated with 10 mM or 100 mM of BeO or
BeSO4, respectively, for 48 h, fixed and stained with DAPI. The nuclei were then photographed under fluorescence using a blue filter
(400 magnification). (B) Western blot analysis of PARP from the THP-1 differentiated macrophages treated with 10 mM or 100 mM of BeO
or BeSO4, respectively, for 48 h. THP-1 macrophages that were untreated were the negative control. Doxycycline treated THP-1 macrophages were
the positive control. All DAPI-stained images and Western blots are representative of three independent experiments.
Table 1 TNF-a (mean  SD pg/mL) levels of the culture supernatants for the THP-1 macrophages that were unstimulated or stimulated with
BeSO4 (10 mM, 100 mM) or BeO (10 mM, 100 mM) for 24 h or 48 h, and for the THP-1 monocytes
Treatment of THP-1 macrophages 24 h Treatment (pg/mL) 48 h Treatment (pg/mL)
Unstimulated 1152.6  40.5 1103.0  16.8
10 mM BeSO4 1061.4  149.2 1081.6  71.7
100 mM BeSO4 1088.2  45.3 935.0  37.6
10 mM BeO 1026.5  56.1 1132.9  38.8
100 mM BeO 1046.4  82.5 1145.7  55.1
THP-1 monocytes Non-detectable Non-detectable























































Subsequent apoptosis studies on chromosomal DNA
fragmentation and PARP cleavage revealed that incorporated
beryllium has negligible cytotoxicity to THP-1 macrophages.
Though adherent CBD/BAL and BeS/BAL macrophages and
DEOHS-1 human CBD macrophage cell line have been
reported to undergo beryllium-stimulated apoptosis
in vitro,38,39 a beryllium-induced apoptosis study has not been
conducted on macrophages from the BAL of normal, healthy,
non-Be-exposed individuals. TNF-a is a potent trigger of
cellular apoptosis and TNF-a elevation has been reported in
beryllium stimulated CBD/BAL cells.34,40,41 In the present
work, ELISA measurement of TNF-a secretion indicated that
for THP-1 macrophages, TNF-a expression was not upregulated
upon beryllium stimulation in comparison to the untreated
control cells. Both Be-stimulated and unstimulated THP-1
macrophages produced a constitutive level of TNF-a around
1000 pg/mL. This enhanced expression, in comparison to the
non-detectable value for THP-1 monocytes reported in literature
and our experiments34,42 could be attributed to the PMA
treatment.43 It is worthy of note that the regulation in TNF-a
production caused by beryllium treatment could have been
masked by this high background level. Anyway, our results are
in agreement with the literature finding that upon in vitro
beryllium stimulation, no upregulation of TNF-a was identified
in most mouse and humanmacrophage cell lines, even including
BeS/BAL cells.34,38–40 As the human CBD/BAL cell population
is a mixed cell population, consisting of macrophages,
lymphocytes and other chronic inflammatory cells, and
those individuals who progressed from BeS to CBD had a
significantly higher percentage of lymphocytes in their BAL
fluid on baseline clinical evaluation,2 the measured TNF-a
elevation in the CBD/BAL cells could be mainly due to
production by the T lymphocytes. Investigations on cell
responses of human BAL macrophages of normal volunteers
to air pollution particulates indicated that cytokine production,
inhibition of host defense mechanisms, and apoptosis were
specifically caused by insoluble components of ambient
particulate matter in the size range of 2.5–10 mm diameter as
compared to insoluble particles of 0.1–2.5 mm diameter
and soluble particles.44 Since BeO and colloidal particles of
beryllium phosphate and hydroxide formed in the culture
medium are much smaller than micron size,12 alveolar macro-
phages could have some level of tolerance to beryllium. This
may explain why most Be-exposed individuals remain healthy
throughout life.
Conclusion
In this study, a new analytical approach for measuring cellular
beryllium content was developed using ICP-MS in place of
conventional radioactive isotope labeling. The influence of the
solubility of beryllium compound, exposure duration, and
beryllium concentration on the incorporation of beryllium
was studied. Our experimental results indicated that THP-1
differentiated macrophages can take up a substantial amount
of beryllium and the major cellular uptake pathway is through
phagocytosis of the particulate form of the beryllium
compound. Subsequent DAPI nuclear staining and Western
blot analysis of PARP cleavage revealed that intracellular
beryllium uptake had a negligible effect on the apoptosis of
THP-1 macrophages compared to the unstimulated macro-
phage control. Meanwhile, no substantial variation of TNF-a
production was observed for THP-1 macrophages upon
beryllium exposure. These data may explain why most
Be-exposed individuals remain healthy throughout life. It is
speculated that the individual’s genetic susceptibility may be
the determining factor in CBD progression and development.
Further experiments with alveolar macrophages of normal,
healthy, non-Be-exposed individuals need to be conducted to
confirm the benign biological effects of cellular beryllium
uptake.
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